This study sought to determine the safety and tolerability of onalespib plus erlotinib in EGFR-mutant NSCLC and evaluate the preliminary efficacy of the combination in EGFR exon 20 insertion (EGFRex20ins) NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.